{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["28"],"submitter":["Wang L"],"pubmed_abstract":["<h4>Background</h4>The coronavirus disease 2019 (COVID-19) pandemic poses a great challenge to the treatment of lung cancer patients.<h4>Materials and methods</h4>The PubMed, Embase, and Web of Science databases were searched for studies published before March 15, 2022, and Stata 14.0 software was used to perform a meta-analysis with a random-effects model. The odds ratio (OR) along with the corresponding 95% confidence interval (CI) was reported.<h4>Results</h4>Our meta-analysis included 80 articles with 318,352 patients involved. The proportion of lung cancer patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was 2.4% (95% CI: 0.02-0.03) prior to the Omicron variant outbreak. Among COVID-19 patients, those with lung cancer showed a higher mortality rate than those with other types of malignant solid tumors (OR = 1.82, 95% CI: 1.61-2.06) and non-cancer patients (OR = 4.67, 95% CI: 3.61-6.05); however, no significant difference was observed in the mortality rate between patients with lung cancer and those with hematologic malignancies (OR = 1.07, 95% CI: 0.85-1.33). SARS-CoV-2 infection significantly increased the mortality rate in lung cancer patients (OR = 8.94, 95% CI: 6.50-12.31). By contrast, the all-cause mortality rate in lung cancer patients (OR = 1.04, 95% CI: 0.69-1.57) and the proportion of patients diagnosed with advanced lung cancer (OR = 1.04, 95% CI: 0.85-1.27) did not significantly change before and after the pandemic.<h4>Conclusions</h4>More attention should be paid on improving the health of lung cancer patients during the COVID-19 pandemic."],"journal":["Translational oncology"],"pagination":["101605"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9760620"],"repository":["biostudies-literature"],"pubmed_title":["Impact of coronavirus disease 2019 on lung cancer patients: A meta-analysis."],"pmcid":["PMC9760620"],"pubmed_authors":["Li X","Li J","Wang Y","Cheng X","Wang L"],"additional_accession":[]},"is_claimable":false,"name":"Impact of coronavirus disease 2019 on lung cancer patients: A meta-analysis.","description":"<h4>Background</h4>The coronavirus disease 2019 (COVID-19) pandemic poses a great challenge to the treatment of lung cancer patients.<h4>Materials and methods</h4>The PubMed, Embase, and Web of Science databases were searched for studies published before March 15, 2022, and Stata 14.0 software was used to perform a meta-analysis with a random-effects model. The odds ratio (OR) along with the corresponding 95% confidence interval (CI) was reported.<h4>Results</h4>Our meta-analysis included 80 articles with 318,352 patients involved. The proportion of lung cancer patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was 2.4% (95% CI: 0.02-0.03) prior to the Omicron variant outbreak. Among COVID-19 patients, those with lung cancer showed a higher mortality rate than those with other types of malignant solid tumors (OR = 1.82, 95% CI: 1.61-2.06) and non-cancer patients (OR = 4.67, 95% CI: 3.61-6.05); however, no significant difference was observed in the mortality rate between patients with lung cancer and those with hematologic malignancies (OR = 1.07, 95% CI: 0.85-1.33). SARS-CoV-2 infection significantly increased the mortality rate in lung cancer patients (OR = 8.94, 95% CI: 6.50-12.31). By contrast, the all-cause mortality rate in lung cancer patients (OR = 1.04, 95% CI: 0.69-1.57) and the proportion of patients diagnosed with advanced lung cancer (OR = 1.04, 95% CI: 0.85-1.27) did not significantly change before and after the pandemic.<h4>Conclusions</h4>More attention should be paid on improving the health of lung cancer patients during the COVID-19 pandemic.","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2025-04-04T22:35:41.713Z","creation":"2025-02-19T03:00:39.512Z"},"accession":"S-EPMC9760620","cross_references":{"pubmed":["36568513"],"doi":["10.1016/j.tranon.2022.101605"]}}